Business Wire

GLEIF

Share
GLEIF Welcomes Pioneering Advances by China Financial Certification Authority (CFCA) Which Pave the Way for Increased LEI Usage in Mass Market Digital Identity Products

The Global Legal Entity Identifier Foundation (GLEIF) has welcomed the first commercial demonstration of Legal Entity Identifiers (LEIs) embedded within digital certificates by the China Financial Certification Authority (CFCA). Simultaneously, GLEIF confirms that CFCA, which is a member of the GLEIF Certification Authorities (CA) Stakeholder Group, is the newest Validation Agent in the Global LEI System and the inaugural CA to sign up for the Validation Agent role.

These developments by CFCA follow the recent launch of the GLEIF CA Stakeholder Group, created as a platform for GLEIF to collaborate with CAs and Trust Service Providers (TSPs) on the coordination and promotion of a global approach to LEI usage across digital identity products. CFCA’s advances are significant because they are the earliest reported successes aligned to the direction of this industry initiative, which is aimed at achieving a critical mass of LEIs embedded within digital certificates.

Stephan Wolf, CEO of GLEIF comments: “This progress by CFCA on both fronts is very welcome as it moves us one step closer to broad LEI usage in digital certificates globally. Realizing the goal of universal LEI usage in digital identity products will be an important step in enhancing trust and creating innovation opportunities across private sector digital identity management applications. Digital certificates linked by an LEI to verified, regularly updated and freely available entity reference data held within the Global LEI System are easier to manage, aggregate and maintain. The result will be significant efficiencies and far less complexity for certificate owners and the provision of greater transparency for all users of the internet and participants within digital exchanges.”

CFCA demo: Using LEIs to link PDF digital certificates to entity reference data in the central GLEIF database

CFCA has become the first market participant to successfully demonstrate a commercial use case of LEIs being embedded in a digital certificate, specifically within the digital certificate issuance process for PDF documents. CFCA’s TrustSign® PDF software supports digital certificate signing and the demo shows the LEI displayed for users alongside certificate properties inside the software.

CFCA’s TrustSign® software digitally stamps a document with a Digital Business Stamp, which embeds an LEI in accordance with ISO 17442-2. When the document is opened and certificate properties are displayed, the LEI is shown and a link provided, via the GLEIF LEI Lookup API, to the trusted, free and easily accessible entity reference data associated with that LEI, held within the central GLEIF database.

Naijin Lu, from CFCA’s Strategic Development Department, comments: “Incorporating LEI into our digital identity products brings many benefits to certificate users, while being very helpful in constructing a digital identity ecosystem. By using GLEIF API for real-time online verification of LEI-related legal entity information, the advantages of digital certificate and LEI can be well integrated in the practice of digital identity to create a better digital identity authentication experience. We are excited to bring forward the first market-based demo of its kind, which proves that the combination of LEI and digital identity products has a bright future. In the future, we will actively explore other application scenarios of LEI in digital identification field, such as vLEI. “

Prior to CFCA’s demo, and in 2019 and 2020 consecutively, GLEIF had brought forward a Proof of Concept when it published its prior year reports with its LEI embedded within the digital certificates of GLEIF’s signing executive officers. Both instances were prior to the publication of ISO 17442-2 in August 2020 which standardized the process of embedding LEIs in digital certificates.

CFCA becomes a Validation Agent within the Global LEI System

In a complementary development which shows CFCA’s commitment to facilitating and promoting LEI issuance in digital certificates, the organization has become the first CA to become a Validation Agent in the Global LEI System. It partnered with a China based LEI issuer, China Financial Computerization Corp (CFCC), to enable customers to obtain LEIs and include them within CFCA products. This partnership, made possible under the GLEIF Validation Framework, provides CFCA customers with a ‘one-stop-shop’ for obtaining their LEIs alongside their identity authentication and information security services.

The Validation Agent Framework, announced by GLEIF in September 2020 , enables institutions to improve their customer experience, accelerate client lifecycle management and reduce costs by using ‘business-as-usual’, KYC onboarding procedures to facilitate LEI issuance for their clients.

Wolf concludes: “The swift and successful integration of the LEI into CFCA’s TrustSign® software is a hugely exciting innovation, which we hope will be a catalyst for other similar demos related to LEI usage in digital certificates to emerge. It shows what is possible thanks to ISO 17442-2 and demonstrates the LEI’s unique value in this important use case. GLEIF is happy to confirm CFCA as not only our newest Validation Agent within the Global LEI System, but also as the first CA to take up that role. Its partnership with CFCC has made that possible. As momentum builds for the LEI to be used outside of regulatory use cases, thanks to recognition of the opportunity and efficiencies it can offer to the private sector, provision of Validation Agent services by a wide range of key actors in the digital ID management and verification ecosystem will be critical to servicing scaled-up LEI demand and simplifying LEI issuance.

We are excited to learn more about CFCA’s advances through their engagement in the GLEIF CA Stakeholder Group. Their developments get this digital identity industry collaboration off to an incredibly strong start. We look forward to working with CFCA and all members of the CA Stakeholder Group as we jointly set out to advance trust and transparency within digital identity products.”

GLEIF welcomes CAs and TSPs to join and participate in the CA Stakeholder Group’s quarterly meetings. For more information or to join the group, please email info@gleif.org

- ENDS -

Full resolution images and logos can be downloaded via this link
https://www.gleif.org/en/newsroom/gleif-graphics-images

Relevant link
https://www.gleif.org/en

Source: Global Legal Entity Identifier Foundation, St. Alban-Vorstadt 5, 4052 Basel, Switzerland
Chairman of the Board: Steven Joachim, CEO: Stephan Wolf
Commercial-Register-No.: CHE-200.595.965, VAT-No.: CHE-200.595.965MWST
LEI: 506700GE1G29325QX363

http://bit.ly/1OXTYLo | http://bit.ly/1Me7uZx | GLEIF Blog: http://bit.ly/1LylXkn http://bit.ly/1LylXkn

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye